Vascular risk factors (VRFs) have been associated with clinically diagnosed Alzheimer disease (AD), but few studies have examined the association between VRF and AD neuropathology (ADNP) in cognitively normal individuals. We used longitudinal data from the National Alzheimer's Disease Center's Uniform Data Set and Neuropathology Data Set to examine the association between VRF and ADNP (moderate to frequent neuritic plaques; Braak stage III-VI) in those with normal cognition. Our sample included 53 participants with ADNP and 140 without ADNP. Body mass index (BMI), resting heart rate (HR), and pulse pressure (PP) were measured at each visit; values were averaged across participant visits and examined annual change in BMI, PP, and HR. Hypertension, diabetes, and hypercholesterolemia were self-reported. In the multivariable logistic regression analyses, average BMI and HR were associated with lower odds of ADNP, and annual increases in HR and BMI were associated with higher odds of ADNP. A previously experienced decline in BMI or HR in late-life (therefore, currently low BMI and low HR) as well as a late-life increase in BMI and HR may indicate underlying AD pathology. Additional clinicopathological research is needed to elucidate the role of changes in late-life VRF and AD pathogenesis. d Subjects reported active/recent or remote/inactive history or taking medication for the condition at any UDS visit.
INTRODUCTION
Neuropathological examination remains the gold standard for the diagnosis of Alzheimer disease (AD) but AD pathophysiologic processes begin many years before symptom onset, a period known as preclinical AD (1) . Depending on age and genetic status, 20%-40% of older adults may exhibit amyloid burden at death despite antemortem normal cognition (2, 3) . However, amyloid plaque accumulation continues with increasing age and may be present in up to 100% of the oldest old (ie centenarians) (4, 5) . The preclinical phase of the AD continuum represents a critical opportunity for therapeutic intervention; however, robust methods to detect AD-related pathophysiological changes during life must first be established. Cerebrospinal fluid (CSF) protein assays and neuroimaging (eg positron emission tomography [PET] ) are currently the gold standards for the detection of AD neuropathology during life (1, 6) . The high expense and invasive nature of CSF assays and neuroimaging limit their utility as frontline detection methods, however, resulting in a need for noninvasive and cost-efficient preclinical AD biomarkers (7) .
Vascular risk factors (VRFs) may be non-specific biomarkers of AD that can be combined with more specific biomarkers and genotypes to aid in predicting AD dementia risk. The epidemiological literature shows an association between VRF and clinically diagnosed incident AD (8) (9) (10) (11) . VRF such as hypertension, type 2 diabetes mellitus (T2DM), obesity, pulse pressure (PP), and resting heart rate (HR) may be particularly useful for identifying individuals in the preclinical stages of AD. For example, hypertension, insulin resistance, and PP, have been linked with greater PET-or CSF-measured AD pathology (eg phosphorylated tau, amyloid-b [Ab] burden) in cognitively healthy older adults (12) (13) (14) (15) . However, inferences regarding the role of VRF in the development of clinical AD are limited due to the unknown etiology of the dementing illness, which could include AD, cerebrovascular disease, other neurodegenerative diseases, or a combination (16) .
Prospective studies with postmortem neuropathological validation are essential for understanding the role of VRF in the pathogenesis of AD neuropathology (ADNP). Although limited, some ex vivo evidence suggests that VRF (eg hypertension, obesity, T2DM) may contribute to ADNP, possibly due to their association with cerebrovascular disease (17) (18) (19) (20) (21) . Cerebrovascular disease may contribute to blood-brain barrier dysfunction and paravascular drainage disruptions that promote Ab deposition and neurodegeneration and interfere with Ab clearance (22, 23) . Nonetheless, the role of VRF as valid biomarkers of preclinical AD remains unclear due to the lack of studies, if any, that have examined VRF and ADNP in an autopsy sample of subjects with normal cognition prior to death. More broadly, the existing literature relies on static assessments of VRF, despite the sensitivity of long-term fluctuations in vascular function with brain pathology (24) .
The objectives of the current study were to examine the cross-sectional and longitudinal relationship between several common VRF and markers of vascular function and ADNP in older adults with antemortem normal cognition from the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS), and Neuropathology Data Set (NDS). This study targeted older adults with normal cognition and excluded those with mild cognitive impairment (MCI) or dementia in order to determine whether a distinct relationship between VRF and ADNP exists during the preclinical phase of AD.
MATERIALS AND METHODS

Participants
Longitudinal, observational study data from the NACC UDS and NDS were used to study participants at 28 past and present US Alzheimer's Disease Centers (ADC) funded by the National Institute on Aging. ADCs have collected annual demographic, clinical, diagnostic, and neuropsychological data on UDS participants with normal cognition, MCI, and dementia since 2005. UDS participants are recruited from populationbased samples, clinics, public recruitment efforts, participant referrals, and other ongoing studies. Because recruitment methods vary, UDS participants are best described as a clinical case series of patients from each ADC. Additional details about the UDS sample are found elsewhere (25) . Data collected between September 2005 and December 2015 were included in this study.
Our sample was restricted to those who had a clinical diagnosis of normal cognition at their last UDS visit before death and underwent neuropathological examination, with data entered into the NACC NDS. We included participants with at least 1 UDS visit within 3 years of their death, and excluded those with no ADNP data or no data on blood pressure, height and weight, and resting HR.
Vascular Risk Factors
Height, weight, systolic (SBP) and diastolic blood pressure (DBP), and resting HR were recorded at each UDS visit. Body mass index (BMI) (kg/m 2 ) was calculated using height and weight data; PP was calculated by subtracting DBP from SBP. We examined PP instead of SBP or DBP because elevated PP in late-life has been associated with AD in previous studies (10, 13) and is expected to rise incrementally with age (26) . In contrast, evidence suggests that mid-life but not latelife high blood pressure is a risk factor for dementia (27) . Moreover, the NACC data do not include mid-life blood pressure measures. For each participant, we calculated the average of these measures across their UDS visits, in order to provide a better representation of the subjects' average BMI in late-life rather than a single measure, which can be easily influenced by age-related illness or terminal decline. In addition, at each visit, participants and their co-participants reported history (recent or remote) of or taking medications for hypertension, diabetes, and hypercholesterolemia, and we created dichotomous variables for each condition (eg yes: any past or present history of hypertension; no: never reported hypertension).
Neuropathology
Neuropathology exam data (NP) are collected using a standardized Neuropathology Form and Coding Guidebook on a subset of UDS participants who died and previously consented to autopsy. Alzheimer disease neuropathologic change (ADNC), according to the current National Institute of Aging-Alzheimer's Association criteria, was added to NACC's Neuropathology Form in January 2014. Due to the small sample size with ADNC data collected to date, we created a surrogate measure, ADNP, which was defined as the presence of moderate to frequent neuritic plaques and Braak stages III-VI. The absence of ADNP was defined as none to sparse neuritic plaques and Braak stages 0-II. Additionally, we used NP data to describe the presence of cerebrovascular disease (large artery infarct or lacune, hemorrhage or microhemorrhage, cortical microinfarct[s], moderate to severe cerebral amyloid angiopathy, moderate to severe atherosclerosis, moderate to severe arteriolosclerosis, hippocampal sclerosis, Lewy body disease, and frontotemporal lobar degeneration).
Demographic, Clinical, and Genetic Variables
UDS participants were evaluated approximately annually using a standardized clinical exam and data on demographics, health history, and medications were ascertained. For this study, the demographic and clinical characteristics included age at initial visit and at death (years), sex, education (years), non-white race, Clinical Dementia Rating sum of boxes score at last visit before death, and number of UDS visits completed. Race was self-reported by the participants and a dichotomous race variable (non-white or white) was created due to the small sample of non-white participants. Race was included in this study to describe the sample, but couldn't be included in the analysis due to the small sample of non-white participants. Additionally, we described the sample by any self-reported history (recent or remote) of cardiovascular disease, thyroid disease, atrial fibrillation, or smoking. History of stroke was determined by any self-reported history, clinical diagnosis, or imaging evidence. We also assessed whether participants reported past or present use of anti-lipid or antihypertensive medications, and described the number of subjects with 1 or more APOE e4 alleles (12% were missing APOE genotype data).
Standard Protocol Approvals, Registrations, and Patient Consents
Research using the NACC database was approved by the University of Washington Institutional Review Board. Informed consent was obtained at the individual ADCs. The NACC data were de-identified.
Statistical Analysis
Descriptive statistics (mean and SD, frequency, and percent) were used to describe the sample demographic, clinical, and neuropathological characteristics, stratified by the presence or absence of ADNP (ADNP-positive or ADNP-negative). Differences were tested using Pearson chi-squared test (categorical variables) or the t-test or Wilcoxon-Mann-Whitney test (normal and non-normal continuous variables, respectively). The Fisher exact test was used when at least 1 comparison group included fewer than 5 participants.
Unadjusted and adjusted logistic regression models with generalized estimating equations examined the association between the VRF (BMI, PP, HR, history of hypertension, diabetes, or hypercholesterolemia) and ADNP. Generalized estimating equations accounted for clustering of the data and the first adjusted model controlled for age at death, sex, and education. The second adjusted model additionally controlled for the presence of at least 1 APOE e4 allele. Annual change in BMI, PP, and HR was assessed by creating interaction terms between these measures and time since the initial visit in years, and each interaction term was included in the multivariable model, first controlling for age at death, sex, and education, and then additionally controlling for presence of at least 1 APOE e4 allele. As a sensitivity analysis, all multivariable models were re-run additionally adjusting for history of stroke, smoking, atrial fibrillation, thyroid disease, and cardiovascular disease, with no significant change in our findings (data not shown).
RESULTS
The sample consisted of a total of 193 subjects, 53 ADNP-positive participants and 140 ADNP-negative participants ( Fig. 1 ). When compared with the ADNP-negative participants, the ADNP-positive participants were older at death and more often had !1 APOE e4 allele (33% in ADNPpositive group; 7% in ADNP-negative group) ( Table 1) . Approximately 44% of the total sample was male, a small minority (8%) was non-white, and Clinical Dementia Rating sum of boxes scores were worse in the ADNP-positive than ADNP-negative group at the last visit before death. The mean number of visits completed was 3.7 visits for the ADNPpositive participants and 4.2 visits for the ADNP-negative participants.
The ADNP-positive group had a significantly lower average BMI, lower average HR, and less cardiovascular disease compared with the ADNP-negative group ( Table 2) . BMI was lower in the ADNP-positive group compared with the ADNPnegative group regardless of the time point examined (initial visit, last visit, average over visits). The 2 groups did not differ in their average values of SBP or DBP over visits, and did not differ on use of anti-hypertensive (eg beta blockers) or antilipid medications except that the ADNP-positive group less often took diuretics. Microinfarcts and amyloid angiopathy were more common in the ADNP-positive group than the ADNP-negative group, with no other differences in neuropathology between the 2 groups ( Table 3 ). The average time between the last clinical visit and autopsy was 12 months for the ADNP-positive group and 11 months for the ADNP-negative group. In the unadjusted analysis, higher average BMI, higher average HR, and history of diabetes were associated with a lower odd of ADNP, whereas average PP, history of hypertension, and history of hypercholesterolemia were not associated with ADNP (Table 4 ). In the adjusted models controlling for age at death, sex, and education, higher average BMI and higher average HR were associated with a lower odds of ADNP, and no other VRF were associated with ADNP ( Table 5 ). The results were similar after additionally controlling for the presence of at least 1 APOE e4 allele ( Table 5 ).
In the multivariable models examining annual change in BMI, PP, and HR (Table 6 ), annual increases in HR and BMI, but not in PP, were associated with an increased odd of ADNP after controlling for age at death, sex, education, and presence of at least 1 APOE e4 allele. However, the magnitude of the association was very small. In these models, having a higher BMI or higher HR at the initial visit was associated with a lower odd of ADNP, and history of hypertension, diabetes, and hypercholesterolemia was not associated with ADNP (Table 6 ).
DISCUSSION
ADNP detection prior to symptom onset is critical for timely intervention of disease modifying therapies. Based on epidemiological associations, some have posited a role for VRF in the pathogenesis of AD (whether it be additive or mechanistic is unclear) and in vivo research has found VRF associated with CSF and PET markers of b-amyloid (12) (13) (14) (15) . However, few studies, if any, have investigated the relationship between VRF and asymptomatic AD using autopsy data. The current study examined VRF and ADNP using a relatively large autopsy sample of NACC participants who were cognitively normal before death. We found that higher average BMI in late-life predicted lower odds of ADNP but a rise in BMI over time predicted higher odds of ADNP. Higher average HR in late-life was associated with lower ADNP burden, whereas annual increases in resting HR predicted higher odds of ADNP. There were no associations with PP, history of diabetes, hypertension, or hypercholesterolemia.
Lower average BMI was associated with higher odds of ADNP in this autopsy sample of older adults with antemortem normal cognition. Previous studies have shown that higher midlife BMI increases risk for the clinical diagnosis of AD (28) (29) (30) , but this effect is diminished or even reversed in latelife (29) (30) (31) (32) (33) . A similar pattern is evident in the ex vivo literature. A higher midlife BMI has been associated with greater ADNP burden in an autopsy sample of 191 subjects with varying levels of cognition (18) . Consistent with our findings, a previous study found that lower BMI proximate to death predicted higher ADNP burden in participants with and without dementia (34) . Although higher BMI in late-life can confer risk for ADNP in the presence of cardiovascular disease, previous autopsy samples and our sample, in particular, included relatively healthy and normal weight older adults (according to standard BMI classification). As such, a higher BMI may serve as a marker of overall general health and survival, and may even be neuroprotective (35) . For example, in a longitudinal population-based study of community-dwelling older adults, being underweight at age 65 predicted worse outcomes (defined by future and active life expectancy, years of healthy life) relative to normal weight individuals. In contrast, being overweight and obese at age 65 was not associated with worse outcomes compared to being normal weight and occasionally predicted better outcomes (36) . Indeed, decreased BMI at older ages can reflect poorer health and is a typical sequela of AD that can occur up to 10 years before the onset of AD symptoms, possibly due to ADNP changes in brain structures (eg medial temporal lobe, olfactory bulb) that may modulate weight control, appetite, olfaction, and taste (37) (38) (39) (40) . Therefore, lower BMI in late-life may serve as an indicator of underlying ADNP changes occurring before cognition is affected.
Additionally, we found that an increase in late-life BMI over follow-up was associated with slightly higher odds of ADNP. A previous longitudinal study found increases in BMI predicted greater dementia risk (41) ; however, the current study is the first to examine the association between changes in late-life BMI over time and ADNP in those with antemortem normal cognition. The mechanisms underlying increases in BMI and ADNP are unclear, but may involve cardiovascular risk and related risk factors for ADNP that can accompany increases in BMI. Inflammation and hormones (eg leptin) that are independently associated with adiposity may also play a role. Notably, we also observed a trivial overall decline in BMI (on average) from the initial visit to the visit closest to death, and thus our findings may be capturing the subset of individuals with increasing BMI over time. These individuals may have been the least likely to have ADNP that disturbed brain regions regulating weight, as is typically observed in the setting of clinically diagnosed AD. Indeed, it is possible that there may be significant individual differences and subtypes in weight change in AD that is dependent on the pathological variants of the disease. Some AD patients may lose weight due to ADNP disruptions in brain regions that modulate weight control, whereas other patients may gain weight with the progression of ADNP. For example, there is a subgroup of those with ADNP who experience neuropathological and behavioral changes consistent with Klüver-Bucy syndrome, including hyperorality, which can be associated with increased eating and weight gain (42, 43) . Longitudinal studies examining BMI across the adult lifespan are needed to improve understanding on the relationship between weight change and preclinical ADNP. Higher average HR was associated with lower odds of ADNP; and annual increases in HR corresponded to greater ADNP burden. Resting HR has clinical utility in cardiovascular disease populations and is associated with cognitive decline in post-stroke patients and individuals with high cardiovascular risk (44, 45) . Limited research has examined resting HR as it relates to aging and neurodegenerative disease although 1 study found higher resting HR to predict worse functional status in older adults independent of cardiovascular disease (46) . Regardless, resting HR is easily influenced by an array of external (eg caffeine) and internal (eg anxiety) stimuli, limiting its reliability, particularly in cross-sectional assessments. In terms of the link between annual increases in resting HR and higher ADNP, the directionality of this relationship is unclear and it is possible that increased resting HR is secondary to a change in central and autonomic control over time that is influenced by brain regions damaged by age-or AD-related pathological changes. For example, the insular cortex is believed to play a role in the regulation of the cardiovascular system (47) , and this brain region can be affected by ADNP before symptom onset (48, 49) . Alternatively, increased HR may contribute to the development of ADNP. Increased HR can be a sign of cardiac problems, predicts incident cardiovascular events (50), and is not typically affected by aging. Therefore, some of the subjects in the sample may have experienced deterioration in overall cardiovascular health over time, potentially leading to cerebrovascular changes, a proposed core feature of AD (51) . Increases in resting HR may also be capturing changes in HR variability (52) , which may be sensitive to AD detection and severity (11) . Overall, this is the first study to report an association between resting HR and ADNP over time but the pathophysiology underpinning this relationship is not known. Further research is needed to replicate our results and clarify the potential biological mechanism(s).
Late-life PP, diabetes, and hypercholesterolemia did not predict ADNP in this study. The older age of the current sample may again partially explain these findings because the presence of these factors during midlife appears to represent the critical risk window for developing AD, and this risk is attenuated or reversed in late-life possibly due to survival bias (21, (53) (54) (55) (56) (57) (58) (59) (60) and the increased prevalence of these conditions with aging. When examined as a continuous variable, PP has previously been found to be unrelated to the clinical diagnosis of AD in a sample of !75 year olds, and other studies have also failed to find an association between antemortem PP and ADNP severity (10, 20) . Interestingly, PP has been linked with in vivo CSF tau and Ab biomarkers, but only among those < 80-years old, and not among those !80 years old (14) . The pathological processes associated with brain aging in the !80-year olds may have attenuated the effects of high PP in predicting underlying ADNP. The early development of ADNP in brain vasomotor centers may also lower blood pressure to decrease risk for cardiovascular disease (61); this might ADNP, Alzheimer disease neuropathology (À, negative; þ, positive); bpm ¼ beats per minute. a Missing data: atrial fibrillation (ADNPþ, n ¼ 0; ADNPÀ, n ¼ 1); thyroid disease (ADNPþ, n ¼ 0; ADNPÀ, n ¼ 1). b Among subjects with at least 2 visits. c Individual-level values were averaged over visits. translate to a null relationship with ADNP burden. Lastly, the presence of T2DM has also been shown to lack association with ADNP in neuropathologically confirmed cases of AD, but T2DM exacerbated the effects of APOE on ADNP (19) . It is possible that the relationship between VRF and ADNP in this sample may also be moderated by factors such as genotype status, though the overall lack of participants with at least 1 APOE e4 allele precluded formal analytic test of this possibility.
There are limitations to the current findings. The assessment of hypertension, diabetes, and hypercholesterolemia using participant and informant self-report could be confounded by subjectivity, memory lapses, etc. More reliable assessments of VRF (eg insulin sensitivity) and examination of fluctuation (eg blood pressure variability) should be the target of future studies examining VRF and ADNP. BMI is a practical method for assessing adiposity, but it is a coarse index and lacks accuracy in older adults due to age-related losses in lean body mass and increased adiposity without weight gain (62) . Future work that uses other anthropometric measures of adiposity (eg waist circumference) that are more reliable in older adult cohorts is needed to validate our findings, particularly in terms of the association between weight change and ADNP. The current sample consisted of normal weight, relatively healthy older adults who agreed to brain donation, representing a highly selective sample that limits the external validity of our findings. Postmortem studies are methodologically problematic because of selection bias (63) and survival bias. For example, the relationship between BMI and ADNP may be distinct in overweight/obese populations, due in part to a higher prevalence of cardiovascular disease and associated VRF (eg diabetes), but these groups may be less likely to be in our sample due to higher risk for premature mortality. Some research suggests that aggregation of VRF into a single measure may be more clinically meaningful in terms of risk for dementia (8) . Additional studies are needed to determine the specific VRF associated with asymptomatic AD, which could be incorporated into an aggregate measure that more strongly predicts Missing data: infarct/lacune (ADNPþ: n ¼ 0; ADNPÀ: n ¼ 1); hemorrhage/microhemorrhage (ADNPþ: n ¼ 0; ADNPÀ: n ¼ 1); amyloid angiopathy (ADNPþ: n ¼ 2; ADNPÀ: n ¼ 2); arteriolosclerosis (ADNPþ: n¼ 14; ADNPÀ: n ¼ 15); hippocampal sclerosis (ADNPþ: n ¼ 0; ADNPÀ: n ¼ 5); Lewy body disease (ADNPþ: n ¼ 0; ADNPÀ: n ¼ 3); FTLD (ADNPþ: n ¼ 15; ADNPÀ: n ¼ 27). asymptomatic AD than the single measures. In addition, microinfarcts and amyloid angiopathy were more frequent in the ADNP-positive than ADNP-negative group. Future work by our group will use advanced statistical modeling to examine cerebrovascular disease as a potential mediator between VRF and ADNP. Finally, the current sample included participants with only normal cognition and excluded those with MCI and dementia in order to investigate whether previously found associations between VRF and ADNP extend to the preclinical stage of AD. As such, MCI and dementia participants were not the target of this research study, and the relationship between VRF and ADNP is likely distinct across the AD continuum due to variability in ADNP burden.
Late-life BMI and resting HR were associated with ADNP in this autopsy sample with antemortem normal cognition. Future clinicopathological research is needed to examine VRF across the lifespan, using robust measures of vascular function and longitudinal biomarkers of ADNP. These future studies will help determine whether epidemiological associations between VRF and AD are due to reverse causality, in which ADNP causes changes in the regions of the brain responsible for HR and weight, or whether VRF are directly responsible for the development of ADNP. Results are reported to the third or fourth decimal place as needed for clarity of interpretation. c Same covariates as Model 1 except additionally controlling for presence of at least 1 APOE e4 allele.
